0001688757-19-000019.txt : 20190429 0001688757-19-000019.hdr.sgml : 20190429 20190429163329 ACCESSION NUMBER: 0001688757-19-000019 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190429 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20190429 DATE AS OF CHANGE: 20190429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ESTABLISHMENT LABS HOLDINGS INC. CENTRAL INDEX KEY: 0001688757 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 981436377 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38593 FILM NUMBER: 19776384 BUSINESS ADDRESS: STREET 1: PO BOX 3140, COMMERCE HOUSE STREET 2: WICKHAMS CAY 1, ROAD TOWN CITY: TORTOLA STATE: D8 ZIP: VG1110 BUSINESS PHONE: 50624342400 MAIL ADDRESS: STREET 1: PO BOX 3140, COMMERCE HOUSE STREET 2: WICKHAMS CAY 1, ROAD TOWN CITY: TORTOLA STATE: D8 ZIP: VG1110 8-K 1 a8ker42519.htm 8-K Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
FORM 8-K
 

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
April 25, 2019
Date of Report (date of earliest event reported)

 
Establishment Labs Holdings Inc.
(Exact name of registrant as specified in its charter)
 
British Virgin Islands
001-38593
Not applicable
(State or other jurisdiction of
incorporation or organization)
(Commission File No.)

(I.R.S. Employer
Identification Number)
Building B15 and 25
Coyol Free Zone
Alajuela
Costa Rica
(Address of principal executive offices) (Zip Code)
 
+506 2434 2400
 
 
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)
 

Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2) of this chapter.

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
 





Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Stock Option Grants

On April 25, 2019, the Compensation Committee approved the grant of stock options to our executive officers. The following table sets forth the number of shares underlying the stock option grants to certain named executive officers:

Named Executive Officer
Position
Stock Options
Juan Jose Chacon-Quiros
Chief Executive Officer and Director
80,000
Salvador Dada
Chief Operating Officer
35,000
Roberto de Mezerville
Chief Technology Officer
25,000
Eddie de Oliveria
Vice President of Sales Brazil
36,000
Eddie de Oliveria
Vice President of Sales Brazil
6,000

The stock options described above were granted under our 2018 Equity Incentive Plan and have a per share exercise price equal to $25.25, the closing price of our common stock as reported on The Nasdaq Capital Market on April 25, 2019.

The option grants for Juan Jose Chacon-Quiros, Salvador Dada and Roberto de Mezerville are subject to a four-year vesting schedule, with 25% vesting one year after a vesting commencement date of January 1, 2020 and 25% each one year anniversary thereafter, subject to the respective optionholder’s continued service with us.

The grant of 36,000 options for Eddie de Oliveria is subject to a four-year vesting schedule, with 25% vesting one year after a vesting commencement date of April 25, 2019 and 25% each one year anniversary thereafter, subject to his continued service with us.

The grant of 6,000 options for Eddie de Oliveria is performance-based and will vest on January 31, 2020 subject to the achievement of certain revenue targets for 2019 and his continued service with us.







SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
ESTABLISHMENT LABS HOLDINGS INC.
 
 
 
 
 
Dated:
April 29, 2019
 
By:
/s/ Renee M. Gaeta
 
 
 
Name:
Renee M. Gaeta
 
 
 
Title:
Chief Financial Officer